ABSTRACT
Background: Polygenic risk scores (PRS) for breast cancer can be used to stratify the population into groups at substantially different levels of risk. Combining PRSs and environmental risk factors will improve risk prediction; however, integrating PRS into risk prediction models requires evaluation of their joint association with known environmental risk factors.
Methods:
Analyses were based on data from 20 studies, datasets analyzed ranged from 3,453 to 23,104 invasive breast cancer cases and similar numbers of controls, depending on the analyzed environmental risk factor. We evaluated joint associations of a 77-single nucleotide polymorphism (SNP) PRS with reproductive history, alcohol consumption, menopausal hormone therapy (MHT), height and body mass index (BMI). We tested the null hypothesis of multiplicative joint associations for PRS and each of the environmental factors, and performed global and a tail-based goodness-of-fit tests in logistic regression models. The outcomes were breast cancer overall and by estrogen receptor (ER) status.
Results:
The strongest evidence for a non-multiplicative interaction with the 77-SNP PRS was for alcohol consumption (P-interaction=0.009), adult height (P-interaction =0.025) and current use of combined MHT (P-interaction =0.038) in ER-positive disease. Risk associations for these factors by percentiles of PRS did not follow a clear dose-response. In addition, global and tail-based goodness of fit tests showed little evidence for departures from a multiplicative risk model, with alcohol consumption showing the strongest evidence for ER-positive disease (P=0.013 for global and 0.18 for tail-based test).
Conclusions:
The combined effects of the 77-SNP PRS and environmental risk factors for breast cancer are generally well described by a multiplicative model. Larger studies are required to confirm possible departures from the multiplicative model for individual risk factors, and assess models specific for ER-negative disease. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Page 4 of 25

INTRODUCTION
Both inherited genetic factors and "environmental" factors, broadly defined as reproductive events (menarche, pregnancy, breast feeding and menopause), modifiable lifestyle (overweight/obesity, alcohol consumption, and physical activity); exogenous hormone medications (oral contraceptive pill and hormone replacement therapy) and medical history, play important roles in breast cancer etiology. 1 Genome-wide association studies have identified more common, low risk single nucleotide polymorphisms (SNPs) that in combination can substantially influence the risk of developing breast cancer. 2, 3 We previously described a 77-SNP polygenic risk score (PRS) for breast cancer; women in the top 1% of the PRS were at three-fold increased risk of developing the disease compared with women in the middle quintile. 4 This PRS explained ~12.6% of the familial relative risk (FRR) of breast cancer. The strength of the association (as measured by the relative risk per standard deviation)
between the 77-SNP PRS and breast cancer risk decreased with increasing age. The association was Page 5 of 25   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  R  e  v  i  e  w  O  n  l  y 5 similar in women with and without a family history, suggesting a multiplicative joint association of the PRS and other familial factors. 4 In combination with environmental risk factors, the polygenic risk defined by the PRS and the residual FRR not explained by the PRS could result in substantial improvements in our ability to distinguish women at different levels of breast cancer risk in the general population, which could then be used to improve prevention and screening strategies for breast cancer. [5] [6] [7] [8] Previous studies have indicated that established genetic and environmental risk factors are likely to combine multiplicatively in their associations with breast cancer risk. [9] [10] [11] [12] A recent report evaluated interactions between a 24-SNP PRS and multiple environmental risk factors. 5 This study showed a good fit of a multiplicative risk model but had limited power to detect interactions, particularly at the extremes of the PRS. We have extended this study to evaluate the joint associations of the 77-SNP PRS and environmental risk factors for breast cancer using data from a larger multi-center study comprising 28,239 cases and 30,445 controls from 20 studies in the Breast Cancer Association Consortium (BCAC). Given that both environmental and genetic risk factors have been shown to differ by disease subtypes defined by estrogen receptor (ER) status, [13] [14] [15] analyses were performed for overall disease and separately for ER-positive and ER-negative disease. This study has immediate relevance as the 77 SNP PRS is currently being incorporated into risk prediction models for genetic counselling.
MATERIALS AND METHODS
Study sample
The study sample comprised 28,239 cases and 30,445 controls of European ancestry from 20 studies:
two case-control studies nested in prospective cohorts, 8 population-based case-control and 10 nonpopulation based case-control studies, all participating in the Breast Cancer Association Consortium (BCAC) (Supplementary Tables 1 and 2 ). Eligible studies had at least 200 cases and 200 controls with genotype data and information on at least one of the environmental risk factors of interest. Studies that oversampled cases with family history of breast cancer were excluded. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  R  e  v  i  e  w  O  n  l  y   6 We excluded participants if they were male, were not of European descent (as defined by genomewide genotype data), or had a missing value for age (age at diagnosis or interview for cases or controls, respectively). Statistical models included subjects with complete data on the specific environmental variable of interest and the adjustment variables. The number of participants available for analysis, therefore, varied by the investigated environmental factor. We also excluded prevalent cases from the cohort studies (date of diagnosis before baseline questionnaire) and cases from case-control studies interviewed more than five years after their diagnosis.
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The relevant ethics committees approved individual studies and all study subjects gave written informed consent.
Data harmonization and variable definitions
Data from different studies were harmonized according to a common data dictionary. A quality assurance procedure was applied that included range and logic checks and comparisons of variable distributions within and between studies. Time-dependent variables were assessed at a reference date defined as the date of diagnosis for cases and the date of interview for controls in case-control studies.
For cohort studies (MCCS and UKBGS), the reference date was the date of last follow-up questionnaire if data were available; otherwise date of baseline questionnaire was used as the reference. 9 The median time between the dates of last interview and diagnosis for cohort study participants was 2.0 years for UKBGS and 7.5 years for MCCS. Because we did not have data on menopausal status, we used the median age (54 years) as a surrogate: women aged <54 years were considered premenopausal and women aged ≥54 years postmenopausal. 9 Seven risk factors for breast cancer were considered: age at menarche, ever being parous, age at first full-term pregnancy (AFTP), adult body mass index (BMI) in postmenopausal women, adult body height, current use of estrogen-progesterone menopausal hormone therapy (MHT), and lifetime average intake of alcohol. Current use of estrogen-progesterone MHT was defined as use within 6 months prior to the reference date. For case-control studies, BMI was calculated based on usual 
Genotyping and Imputation
The rsnumbers for the 77 SNPs included in this report are shown in Supplementary Table 4 .
Genotype data for 76 of the 77 SNPs included in the PRS were generated as part of the Collaborative Oncological Gene-environment Study (COGS; www.nature.com/icogs) using an Illumina iSelect array (iCOGS) in all studies except BREOGAN. One SNP (rs78540526) was not genotyped but imputed using SHAPEIT and IMPUTEv2, using 5Mb non-overlapping intervals, as previously described. 16 Genotyping methods and quality control criteria have also been previously described. 17 Briefly, SNPs were excluded if the call rate was <95%, P for Hardy-Weinberg-Equilibrium test <10 -7 , the concordance rate in duplicate samples was <98%, or if the SNP was monomorphic. Study participants were excluded from analyses if the overall genotyping call rate was <95% over the whole iCOGS array or if heterozygosity deviated from that expected in the general population (either lower or higher, P <10 -6 ).
Genotyping for BREOGAN was performed at the Spanish National Genotyping Center (CeGen-ISCIII), using the Sequenom MassARRAY Genotyping system (technology iPLEX GOLD) following the manufacturer's instructions. The SNPs were analyzed using 4 assays (Assay Design v4 software) and genotyping calls were generated using the software Typer analyzer v4.0.20. The quality criteria described above were applied. The assay for rs7726159 failed and imputation of genotypes could not 
Statistical Methods
We investigated interactions between environmental risk factors for breast cancer and the PRS as a measure of the combined effects of 77 established SNPs on breast cancer risk. The calculation of the PRS for overall breast cancer and the PRS specific for ER-positive and ER-negative disease has been previously described. 4 Briefly, the PRS was derived for each study subject using the formula:
where β k was the per-allele log odds ratio (OR) for breast cancer associated with the minor allele for SNP k, x k was the number of alleles for that same SNP (0, 1 or 2), and n=77 was the total number of SNPs (except for BREOGAN where we derived a 75 SNP PRS). To derive the ER-positive PRS, allele counts were weighted by ER-positive specific effect estimates; likewise, ER-negative specific effect estimates were used to derive the ER-negative PRS. The log ORs for each of the SNPs used to calculate the PRS were estimated using data in this report and are provided in Supplementary Table   4 . These estimates are very close to those in our previous report, 4 which is expected given the large overlap in study populations.
ORs and 95% confidence intervals (CIs) were estimated using logistic regression models for overall breast cancer risk and by ER status of the tumor. Initial analyses included all studies with available data, regardless of study design, and considered each environmental variable one at a time. Models were adjusted for study (indicator variables), age and seven ancestry-informative principal components (for models including PRS). All models also included an interaction term between study design (population-based/cohort vs non-population based; see Supplementary Table 1 ) and the environmental variable of interest, to account for potential heterogeneity of main effects by design.
Because estimates of main effects of environmental variables from non-population-based designs are To assess the goodness of fit of a multiplicative model, we also performed, for each risk factor, a global goodness of fit test and a recently developed tail-based goodness of fit test to assess deviations from logistic models at the extremes of the risk distribution. 18 For goodness of fit tests, analyses were restricted to population-based/cohort studies to remove the contribution of nonpopulation based studies to the main effect estimates of environmental risk factors as these are more prone to biases. The goodness of fit tests were not fit for ER-negative disease, as the number of controls and the number of cases available for analysis was too small to provide reliable estimates, particularly in the tails.
The statistical analysis was conducted using SAS 9.3 and R (version 3.0.2). All tests performed were two-sided.
RESULTS
A total of 28,241 cases and 30,445 controls from 20 studies contributed data to at least one analysis.
The numbers of cases and controls from each of the studies are shown in Supplementary Table 2 .
The associations between the 77-SNP PRS for overall and subtype specific breast cancer are shown in Supplementary Figure 1 . As shown previously using a similar study population as in this report, 4 associations were stronger for ER-positive than ER-negative disease. controls for parity, and multiplicative interaction parameters showed no evidence for heterogeneity between population-based/cohort and non-population-based study designs (Supplementary Table   5 ). We found no evidence for interactions in ER-negative disease ( Table 1 ). Figure 1 shows the estimated ORs (95%CI) for the risk of ER-positive breast cancer and each of the environmental risk factors stratified by percentiles of the PRS (see Supplementary Figure 2 for results for overall breast cancer and by ER status). It should be noted that interaction tests in (Figure 1) : the interaction for alcohol was mainly driven by the relatively large OR estimate for the lowest percentile of the PRS; the OR estimates for height were stronger for the middle categories of PRS; and the ORs for MHT showed more of a dose-response pattern, although not entirely consistent across categories of PRS. replicated in independent studies with appropriate study designs, particularly in view of the lack of a clear dose-response pattern for the interactions in our report. Our result should also be interpreted with caution because of multiple hypothesis testing and the relatively low power (as reflected by the wide confidence intervals in estimates of interaction parameters) that can lead to a higher probably of false positive findings for a given significance level.
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The 77 SNP PRS in our analysis is more predictive than the 24 SNP PRS evaluated in the BPC3 report since it includes all 24 SNPs plus additional SNPs identified in subsequent genome-wide association studies. However, the 77-SNP PRS could be over-fitted since our study population largely overlaps with populations in genome wide association studies that lead to the discovery of most of known SNPs. 17, 23 Nevertheless, over-fitting of the PRS is unlikely to bias the assessment of interactions with environmental risk factors.
A strength of our study is the large total sample size; however, data for some risk factors, particularly alcohol consumption and use of MHT, was only available from a subset of studies or was missing for a substantial number of participants. In addition, our report includes studies with different study designs: ten of 20 studies were non-population-based case-control studies that are prone to biases in assessing associations with environmental risk factors. To address this limitation, we included an interaction term for the environmental exposure and study design (population-based (including cohorts) versus non-population-based), and used only main effects estimates from population-based studies. In contrast, we used all data available for estimation of multiplicative interaction parameters since they are less susceptible to differential measurement error in case-control studies than main effect parameters, 24 and showed no evidence for heterogeneity across study designs. controls. 21 Larger studies are needed to further evaluate the joint associations between PRS and these factors. More data than that included in this report will also be required to assess the joint effects for ER-negative disease, where the sample sizes and effect sizes for some factors are smaller.
In summary, our results provide support for the assumption of multiplicative joint associations between PRS and environmental risk factors in the development of risk prediction models for breast cancer; however, small departures are possible and require further investigation. Risk prediction tools based on validated models that can be easily implemented in clinical practice will be needed for the evaluation and ultimate adoption of risk-stratification-based strategies in breast cancer prevention and screening. Table 1 . Odds ratios and 95% confidence intervals for multiplicative interaction between polygenic risk score and environmental risk factors of breast cancer, for all and ER-positive breast cancers, based on population-based and non-population-based studies. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 and by ER status of the tumor, based on population-based studies.
TABLES AND FIGURES
Supplementary Table 4 . SNPs included in polygenic risk score and effect sizes for association with breast cancer or subtypes of the disease.
Supplementary Table 5 . Odds ratios and 95% confidence intervals for multiplicative interaction between 77-SNP polygenic risk score (PRS) and environmental risk factors of breast cancer by study design category.
Supplementary Figure 1.
Odds ratios and 95% confidence intervals for percentiles of the 77-SNP polygenic risk score (PRS), for all, ER-positive breast cancer and ER-negative breast cancer, based on population-based and non-population-based studies.
Supplementary Figure 2.
Odds ratios and 95% confidence intervals for breast cancer risk factors by percentiles of the 77-SNP polygenic risk score (PRS) for all, ER-positive breast cancer and ER-negative breast cancer, based on population-based and non-population-based studies. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Table 1 . Odds ratios and 95% confidence intervals for multiplicative interaction between polygenic risk score and environmental risk factors of breast cancer, for all, ERpositive breast cancer and ER-negative breast cancer, based on population-based and non-population-based studies 1 Adjusted for reference age, study, ancestry-informative principal components and an interaction term between environmental factor and study design (population-based vs. non-population-based). Models used to assess association with use of combined MHT have been further adjusted use of other MHT preparations. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48 
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